Regencell Bioscience Reports H1 2025 Financial Results: Comprehensive Loss of $1.8M, EPS Declines to $0.36

Reuters

Jun 30, 2025

Regencell Bioscience Reports H1 2025 Financial Results: Comprehensive Loss of $1.8M, EPS Declines to $0.36

Regencell Bioscience Holdings Limited (Nasdaq: RGC) announced its unaudited condensed consolidated interim financial results for the six months ended December 31, 2024. The company reported a comprehensive loss of $1.8 million compared to a loss of $2.1 million for the same period in 2023. The net comprehensive loss attributable to shareholders of the company was $1.8 million, with a loss per share of $0.36. The results include a foreign currency translation adjustment, resulting in a net loss reduction attributed to currency fluctuations. The company's weighted average number of ordinary shares remained unchanged at 494.5 million, accounting for the 38-for-1 share split effective June 13, 2025. No specific outlook or guidance was provided in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regencell Bioscience Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-059287), on June 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2547944750"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2547944750\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2547944750?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547944750","market":"us","top_or_hot":-1,"title":"Regencell Bioscience Reports H1 2025 Financial Results: Comprehensive Loss of $1.8M, EPS Declines to $0.36","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Regencell Bioscience Reports H1 2025 Financial Results: Comprehensive Loss of $1.8M, EPS Declines to $0.36\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Regencell Bioscience Holdings Limited (Nasdaq: RGC) announced its unaudited condensed consolidated interim financial results for the six months ended December 31, 2024. The company reported a comprehensive loss of $1.8 million compared to a loss of $2.1 million for the same period in 2023. The net comprehensive loss attributable to shareholders of the company was $1.8 million, with a loss per share of $0.36. The results include a foreign currency translation adjustment, resulting in a net loss reduction attributed to currency fluctuations. The company's weighted average number of ordinary shares remained unchanged at 494.5 million, accounting for the 38-for-1 share split effective June 13, 2025. No specific outlook or guidance was provided in the announcement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regencell Bioscience Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-059287), on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regencell Bioscience Reports H1 2025 Financial Results: Comprehensive Loss of $1.8M, EPS Declines to $0.36</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegencell Bioscience Reports H1 2025 Financial Results: Comprehensive Loss of $1.8M, EPS Declines to $0.36\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-30 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Regencell Bioscience Reports H1 2025 Financial Results: Comprehensive Loss of $1.8M, EPS Declines to $0.36\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Regencell Bioscience Holdings Limited (Nasdaq: RGC) announced its unaudited condensed consolidated interim financial results for the six months ended December 31, 2024. The company reported a comprehensive loss of $1.8 million compared to a loss of $2.1 million for the same period in 2023. The net comprehensive loss attributable to shareholders of the company was $1.8 million, with a loss per share of $0.36. The results include a foreign currency translation adjustment, resulting in a net loss reduction attributed to currency fluctuations. The company's weighted average number of ordinary shares remained unchanged at 494.5 million, accounting for the 38-for-1 share split effective June 13, 2025. No specific outlook or guidance was provided in the announcement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regencell Bioscience Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-059287), on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RGC","symbol_name":"脑再生科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL5TbWMj:1","article_id":"2547944750","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547944750","pubTimestamp":1751288481,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Regencell Bioscience Holdings Limited  announced its unaudited condensed consolidated interim financial results for the six months ended December 31, 2024. The company reported a comprehensive loss of $1.8 million compared to a loss of $2.1 million for the same period in 2023. The net comprehensive loss attributable to shareholders of the company was $1.8 million, with a loss per share of $0.36. The results include a foreign currency translation adjustment, resulting in a net loss reduction attributed to currency fluctuations. The company's weighted average number of ordinary shares remained unchanged at 494.5 million, accounting for the 38-for-1 share split effective June 13, 2025. No specific outlook or guidance was provided in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should no","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RGC":"脑再生科技"},"translate_title":"Regencell Bioscience报告2025年上半年财务业绩：综合亏损180万美元，每股收益下降至0.36美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGC":0.9},"content_text":"Regencell Bioscience Reports H1 2025 Financial Results: Comprehensive Loss of $1.8M, EPS Declines to $0.36\n    \n\n        Regencell Bioscience Holdings Limited (Nasdaq: RGC) announced its unaudited condensed consolidated interim financial results for the six months ended December 31, 2024. The company reported a comprehensive loss of $1.8 million compared to a loss of $2.1 million for the same period in 2023. The net comprehensive loss attributable to shareholders of the company was $1.8 million, with a loss per share of $0.36. The results include a foreign currency translation adjustment, resulting in a net loss reduction attributed to currency fluctuations. The company's weighted average number of ordinary shares remained unchanged at 494.5 million, accounting for the 38-for-1 share split effective June 13, 2025. No specific outlook or guidance was provided in the announcement.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regencell Bioscience Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-059287), on June 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}